Spikevax sales slide predicted by analyst

3 February 2023
moderna_big

When Moderna (Nasdaq: MRNA) presents its 2022 financial results later this month, sales of its COVID-19 vaccine Spikevax are expected to be around $19.5 billion, a figure the young biotech company could only have dreamt about a few years ago.

This makes it the second highest selling COVID-19 vaccine, behind only Pfizer’s (NYSE: PFE), which had 2022 sales of $37.8 billion.

"Spikevax could struggle to compete with direct competitors Comirnaty and new entrants such as COVID-19 therapeutics"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology